Introduction
In December 2019, world faced the outbreak of COVID-19 of which the
SARS-CoV-2, was known as the causative pathogen. As the virus found its
way world spread, in beginning of march 2020 WHO officially declared the
disease as a pandemic (1).
Inevitably, massive vaccination became the only way to prevent and
control the unleashed pandemic (2). In almost two years 155 vaccine
candidates were developed which 23 of them were authorized fallowing
different strategies (inactivated, mRNA, viral vector,
nanoparticle-based peptide vaccines, etc.). All authorized vaccines have
shown promising efficacy; however, the AEs and SAEs remained an unknown
challenge (3). The most common AEs were injection site pain or
tenderness, fatigue, headache, rash, fever, chill, as well as myalgia,
and arthralgia (4). Moreover, thrombosis and thrombocytopenia,
myocarditis or pericarditis, inflammatory myositis, and autoimmune
diseases were frequently reported SAEs (4, 5). To date few, studies have
reported cases of ocular inflammatory AEs after the first or second dose
of vaccination, including white dot syndrome, pan uveitis, choroiditis,
along with scleritis and scleritis (6, 7).
Herein, we reported a case of 52-year-old woman presented with simple
scleritis following third dose of Sinopharm COVID-19 vaccination.